- Founder(s): Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier
- Established: March 2016
- CEO(s): Sebastian Meier-Ewert
- Employees: >20
- Financial Data: Privately funded
- Website: iomx.com
This startup is developing next-generation cancer immunotherapies targeting novel immune evasion pathways.
iOmx focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the company has already identified a number of novel targets and analyzed their mode of action.
Their location advantages include a critical mass of biotech companies, life science institutions and service providers in addition to a high quality of life.